6550 Polaris Pharmaceuticals-KY Suspension of Phase III Clinical Trial for LMS
NQ Score
48/100
N1 Content Completeness
10
AI Summary (NQ-processed)
Polaris Pharmaceuticals-KY announced the suspension of its Phase III clinical trial for ADI-PEG 20 in treating leiomyosarcoma (LMS), following recommendations from the Data Safety Monitoring Board (DSMB). The company plans to optimize the trial design.
AI Analysis
Frequently Asked Questions
- Q: Why was the clinical trial suspended?
- A: Based on DSMB recommendations to optimize the trial design.